The long-term social value of granulocyte colony-stimulating factors

Am J Manag Care. 2019 Oct;25(10):486-493.

Abstract

Objectives: Febrile neutropenia (FN) is a life-threatening complication of chemotherapy that can lead to hospitalizations, chemotherapy dose reductions or delays, and mortality. Granulocyte colony-stimulating factor (G-CSF) prophylaxis reduces the incidence of FN, enabling patients to undergo and remain on myelosuppressive chemotherapy. We estimate the benefits of continuing current G-CSF use patterns and an alternative that aligns prophylactic G-CSF use with guideline recommendations.

Study design: Using The Health Economics Medical Innovation Simulation microsimulation, we estimated lifetime social value (SV) of prophylactic G-CSF for a nationally representative US population with breast, lung, and gynecological cancers and non-Hodgkin lymphoma.

Methods: SV estimates included the cost of G-CSF, FN, chemotherapy relative dose intensity (RDI) less than 85% (RDI<85%), medical spending, and deaths for 3 scenarios: current use (current G-CSF use), targeted use (100% G-CSF use among patients with high FN risk), and reduced use (current G-CSF use reduced by 20% across all FN risk categories).

Results: Over 10 years, current use, compared with no G-CSF use, would decrease cases of FN by 3.3 million, prevent 354,000 cases of RDI<85%, and generate $96 billion in SV. Compared with current use, targeted use would decrease cases of FN by an additional 3.3 million, prevent 355,000 more cases of RDI<85%, and generate another $119 billion in SV. Reduced use would increase FN and RDI<85%, lowering SV by $18 billion compared with current use.

Conclusions: Current use of G-CSF prophylaxis would provide $96 billion in SV over the next 10 years. Targeting G-CSF prophylaxis to align with guidelines would more than double SV, highlighting the substantial value of appropriate FN risk assessment and targeted G-CSF prophylaxis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chemotherapy-Induced Febrile Neutropenia / prevention & control*
  • Computer Simulation
  • Cost-Benefit Analysis
  • Dose-Response Relationship, Drug
  • Granulocyte Colony-Stimulating Factor / administration & dosage*
  • Granulocyte Colony-Stimulating Factor / economics*
  • Health Expenditures / statistics & numerical data
  • Health Services / economics
  • Health Services / statistics & numerical data
  • Humans
  • Models, Econometric
  • Neoplasms / drug therapy
  • Neoplasms / epidemiology*
  • Quality-Adjusted Life Years
  • Severity of Illness Index

Substances

  • Granulocyte Colony-Stimulating Factor